E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Protein-Tyrosine Phosphatase Inhibitors"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Bioorganic Chemistry".

Deadline for manuscript submissions: 20 November 2017

Special Issue Editors

Guest Editor
Prof. Jeroen den Hertog

1. Hubrecht Institute–Koninklijke Nederlandse Akademie van Wetenschappen (KNAW) and University Medical Center Utrecht, Utrecht, The Netherlands
2. Institute of Biology Leiden, Leiden University, Leiden, The Netherlands
Website | E-Mail
Interests: protein-tyrosine phosphatase; signaling; PTEN; SHP2; RPTPalpha; zebrafish; gastrulation; cancer; Noonan Syndrome
Guest Editor
Prof. Rob M. J. Liskamp

School of Chemistry, University of Glasgow, Joseph Black Building, University Avenue, Glasgow, UK and Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
Website1 | Website2 | E-Mail
Interests: peptidomimetics; protein mimics; synthetic vaccines; synthetic antibodies; protease inhibitors; protein phosphatase inhibitors; electrophilic traps; cancer; infections; inflammation

Special Issue Information

Dear Colleagues,

Protein-tyrosine phosphatases counteract protein-tyrosine kinases and, hence, have a central role in development and disease, as regulators of phosphotyrosine levels in cellular proteins. Protein-tyrosine phosphatases have been heralded as drug targets for decades, particularly for conditions such as cancer and diabetes. Over the years, many catalytic site-directed protein-tyrosine phosphatase inhibitors have been generated; however, the catalytic sites of protein-tyrosine phosphatases are highly conserved, which compromises the selectivity of small molecule compounds. In addition, the substrates of protein-tyrosine phosphatases contain negatively-charged phosphotyrosine, which hampers the transduction of substrate-mimetic inhibitors across the cell membrane. Recently, several allosteric inhibitors have been developed that are highly selective and do not contain negative charges. Looking forward, there is a bright future for small molecule inhibitors of protein-tyrosine phosphatases.

Prof.  Jeroen den Hertog
Prof. Rob M. J. Liskamp
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • protein-tyrosine phosphatases
  • (covalent) inhibitors
  • small molecules
  • peptidomimetics
  • allosteric inhibitors
  • cancer
  • diabetes

Published Papers

This special issue is now open for submission.
Back to Top